Coherus Oncology, Inc. (CHRS) Financial Statements
Coherus Oncology, Inc. (CHRS) reported trailing twelve-month revenue of $50.9M (up 61.0% year on year) and net income of -$132.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CHRSCoherus Oncology, Inc.Follow CHRS — free
—
Price chart with a free account
- Market cap
- 156.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.1 | 30.0 | 190.1 | 1.6 | 356.1 | 475.8 | 326.6 | 211.0 | 257.2 | 26.4 | 42.2 | 50.9 | |
| Gross profit | — | — | — | — | — | 438.2 | 269.0 | 141.0 | 98.3 | 17.7 | 28.4 | 35.1 | |
| Research & development | 78.2 | 213.1 | 254.4 | 162.4 | 94.2 | 142.8 | 363.1 | 199.4 | 109.4 | 91.8 | 108.9 | 101.2 | |
| Operating income | -64.7 | -219.1 | -115.9 | -232.1 | 107.8 | 156.3 | -263.9 | -256.9 | -203.2 | -199.7 | -181.1 | -158.7 | |
| Pre-tax income | -87.2 | -223.9 | -127.8 | -238.3 | 92.8 | 135.7 | -287.1 | -291.8 | -238.3 | -215.4 | -183.1 | -161.1 | |
| Income tax | — | — | 0.0 | 0.0 | 2.9 | 3.5 | 0.0 | 0.0 | -0.4 | 0.0 | 0.0 | — | |
| Net income | -87.1 | -223.3 | -127.3 | -238.2 | 89.8 | 132.2 | -287.1 | -291.8 | -237.9 | 28.5 | 168.0 | -132.1 | |
| Diluted EPS ($) | -10.64 | -6.01 | -3.04 | -4.48 | 1.23 | 1.62 | -3.81 | -3.76 | -2.53 | 0.25 | 1.43 | -0.85 | |
| Diluted shares (mn) | — | — | — | — | 73.2 | 83.5 | 75.4 | 77.6 | 94.2 | 114.6 | 117.1 | — |
USD millions · SEC XBRL
Coherus Oncology, Inc. — questions
- What is Coherus Oncology, Inc.'s revenue?
- $50.9M over the twelve months to 2026-06-30, up 61.0% year on year, from its 10-Q and 10-K filings.
- What is Coherus Oncology, Inc.'s net income?
- -$132.1M over the twelve months to 2026-06-30.
- What are Coherus Oncology, Inc.'s diluted earnings per share?
- $-0.85 over the twelve months to 2026-06-30.
Every figure on this page comes from Coherus Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.